Answers are grounded in this paper and cite their sources.
Photodynamic therapy (PDT) depends on the spatial and temporal overlap of photoactive photosensitizer, light, and oxygen. Formulation improvements are therefore meaningful only when they change the exposure available during irradiation and improve an indication-relevant outcome. This narrative review links delivery and activation to drug–light interval selection, oxygen-dependent dosimetry, combination-treatment sequence, and clinical implementation. Representative comparisons support three conclusions. First, cellular uptake and total tumor concentration incompletely describe active exposure, and the preferred irradiation window depends on whether treatment targets vasculature, tumor cells, or light-triggered drug release. Second, temporal fractionation and oxygen-informed dose estimates can improve treatment interpretation within specific systems, but their thresholds are not transferable without validation. Third, programmed release and combination efficacy provide weaker evidence for an optimal sequence than comparisons that isolate treatment order; mathematical synergy also depends on the model and endpoint. Human studies establish the feasibility of multivariable monitoring more clearly than the clinical benefit of feedback-based treatment. We propose conditional priorities based on measured limitations in light coverage, active photosensitizer availability, oxygen supply, and systemic disease control, together with criteria for stopping unnecessary increases in formulation complexity. Translation requires reproducible potency, compatible devices, and comparative patient benefit across the complete treatment pathway.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: